Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer

Martin J Edelman,Mikhail Dvorkin, Konstatin Laktionov,Alejandro Navarro,Oscar Juan-Vidal,Vadim Kozlov,Gil Golden,Odette Jordan,C Q Deng, Dmitriy Bentsion, Christos Chouaid, Hristo Dechev,Afshin Dowlati,Natalia Fernández Núñez,Olexandr Ivashchuk, Ivane Kiladze, Tsira Kortua,Natasha Leighl, Aleksandr Luft,Tamta Makharadze,YoungJoo Min,Xavier Quantin

Lung Cancer（2022）

Cited 9|Views30
No score
Abstract
•There has been relatively little progress in the treatment of small cell lung cancer.•Disialoganglioside 2 is commonly expressed in SCLC.•Dinutuximab, an anti-GD2 antibody is approved for neuroblastoma and is synergistic with irinotecan.•Dinutuximab + irinotecan vs. topotecan vs irinotecan in recurrent SCLC did not improve outcomes.
More
Translated text
Key words
GD2,NB
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined